PharmAthene Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Altimmune Inc (ALT)
Altimmune Inc stock price live, this page displays NASDAQ ALT stock exchange data. View the ALT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Altimmune Inc real time stock price chart below.
What Is the Altimmune Inc Stock Price Today?
The Altimmune Inc stock price today is 3.66.
What Is the Stock Symbol for Altimmune Inc?
The stock symbol for Altimmune Inc is ""ALT.""
What Stock Exchange Does Altimmune Inc Trade On?
Altimmune Inc is listed and trades on the NASDAQ stock exchange.
Is Altimmune Inc a Good Stock to Buy?
Determining whether Altimmune Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALT quote. (ISIN: US02155H2004)
What Is the Altimmune Inc Stock Price Today?
The Altimmune Inc stock price today is 3.66.
What Is the Stock Symbol for Altimmune Inc?
The stock symbol for Altimmune Inc is ""ALT.""
What Stock Exchange Does Altimmune Inc Trade On?
Altimmune Inc is listed and trades on the NASDAQ stock exchange.
Is Altimmune Inc a Good Stock to Buy?
Determining whether Altimmune Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALT quote. (ISIN: US02155H2004)
Currency in USD
3.66
-0.02(-0.54%)
Real-time Data·
Fair Value
An estimate of a Altimmune's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.64
3.74
52 wk Range
2.90
11.16
ALT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ALT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Altimmune's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.643.74
52 wk Range
2.9011.16
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Altimmune's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
17.20
Upside
+369.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
7 analysts have revised their earnings upwards for the upcoming period
- Form 8K Altimmune Inc For: 12 August
- Investing.com
- PharmAthene Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Altimmune appoints Jerry Durso as board chairman
- Investing.com
- PharmAthene Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - PharmAthene Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 10Q Altimmune Inc For: 12 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Altimmune Inc Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune Inc SWOT Analysis
Pemvidutide Promise | Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results |
Expanding Horizons | Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease |
Clinical Milestones | Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025 |
Market Potential | Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone |
Altimmune Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.27 beats -$0.31 forecast, driving 5.62% stock rise to $3.57 in premarket trading
- Total cash increased 40% to $183.1M; R&D expenses down to $17.2M from $21M YoY; net loss improved to $22.1M from $24.6M YoY
- NASH treatment shows promising trial results; end-of-Phase II FDA meeting scheduled for Q4 2025
- New Board Chairman Jerry Durso appointed; company raised $88M in equity and secured $100M debt facility
- Advancing Phase II trials for AUD and ALD; 48-week NASH treatment data expected later this year
Last Updated: 12/08/2025, 14:30
Read Full TranscriptCompare ALT to Peers and Sector
Metrics to compare | ALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.7x | −4.1x | −0.5x | |
PEG Ratio | −0.14 | 0.13 | 0.00 | |
Price/Book | 2.0x | 0.5x | 2.6x | |
Price / LTM Sales | 16,195.2x | 124.1x | 3.3x | |
Upside (Analyst Target) | 391.8% | 217.8% | 40.6% | |
Fair Value Upside | Unlock | −5.9% | 5.3% | Unlock |
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 17.20
(+369.95% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.27 / -0.31
Revenue / Forecast
5.00K / 833.00M
People Also Watch
FAQ
What Stock Exchange Does Altimmune Trade On?
Altimmune is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Altimmune?
The stock symbol for Altimmune is "ALT."
What Is the Altimmune Market Cap?
As of today, Altimmune market cap is 324.79M.
What Is Altimmune's Earnings Per Share (TTM)?
The Altimmune EPS (TTM) is -1.17.
When Is the Next Altimmune Earnings Date?
Altimmune will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is ALT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Altimmune Stock Split?
Altimmune has split 2 times.
How Many Employees Does Altimmune Have?
Altimmune has 59 employees.
What is the current trading status of Altimmune (ALT)?
As of 15 Aug 2025, Altimmune (ALT) is trading at a price of 3.66, with a previous close of 3.68. The stock has fluctuated within a day range of 3.64 to 3.74, while its 52-week range spans from 2.90 to 11.16.
What Is Altimmune (ALT) Price Target According to Analysts?
The average 12-month price target for Altimmune is USD17.2, with a high estimate of USD28 and a low estimate of USD1. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +369.95% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.